MedTrace Logo

Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease

NCT04057807 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-02-05

Study results available
· View outcomes & findings →

Summary

To examine the differences in the capacity to activate microglia in patients with Alzheimer's Disease (AD) compared to age-comparable cognitively normal subjects and younger healthy controls.

Conditions

  • Alzheimer Disease

Interventions

DRUG

LPS

LPS (0.4 ng/kg)

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Adam Mecca, M.D., Ph.D. · Yale University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-15
Primary Completion
2022-07-27
Completion
2022-07-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04057807 on ClinicalTrials.gov